Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04272034
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:11.833304+00:00
Published At
2025-10-16T00:00:00+00:00
Record Updated At
2025-10-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Solid Tumors", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma, HCC", "Cervical Cancer", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma", "Cyclin-dependent Kinase 12 Mutated Tumors", "Basal Cell Carcinoma (Unresectable or Metastatic)", "Sarcomatoid Renal Cell Carcinoma", "Clear Cell Ovarian or Endometrial Carcinoma", "Anal Carcinoma", "Squamous Cell Penile Carcinoma", "DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-16"
protocolSection.identificationModule.nctId
"NCT04272034"
protocolSection.identificationModule.officialTitle
"A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Solid Tumors (protocolSection.conditionsModule.conditions)
  • MSI-H/dMMR Tumors (protocolSection.conditionsModule.conditions)
  • Cutaneous Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma, HCC (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Small-cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Mesothelioma (protocolSection.conditionsModule.conditions)
  • PD-L1 Amplified Tumor (9p24.1) (protocolSection.conditionsModule.conditions)
  • Nasopharyngeal Carcinoma (protocolSection.conditionsModule.conditions)
  • Cyclin-dependent Kinase 12 Mutated Tumors (protocolSection.conditionsModule.conditions)
  • Basal Cell Carcinoma (Unresectable or Metastatic) (protocolSection.conditionsModule.conditions)
  • Sarcomatoid Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Clear Cell Ovarian or Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Anal Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Penile Carcinoma (protocolSection.conditionsModule.conditions)
  • DNA Polymerase Epsilon Mutated Tumors (P286R and V411L) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.